Cognition Therapeutics, Inc.
NASDAQ:CGTXBiotechnology
Healthcare
$0.60 -0.70%
-$0.01 today
- Market cap
- $57.12M
- Beta
- 1.75
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$0.22
52W Low $0.25High $3.83
Volume 0.33M
Average 1.23M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$24.59M
FY 2025 · Annual
Investing Cash Flow
$9,000.00
FY 2025 · Annual
Financing Cash Flow
$36.57M
FY 2025 · Annual
+55.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (11.72M) | (21.4M) | (25.79M) | (33.97M) | (23.49M) |
| Depreciation & Amortization | 93K | 235K | 252K | 266K | 228K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.18M | 3.57M | 4.35M | 3.75M | 2.09M |
| Change in Working Capital | 2.84M | (943K) | 4.85M | 1.29M | (3.46M) |
| Accounts Receivables | (1.11M) | (1.41M) | 2.39M | (1.41M) | (7.24M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.17M | (1.09M) | 0 | 0 | 3.51M |
| Other Working Capital | 1.79M | 1.56M | 2.46M | 2.69M | 270K |
| Other Non-Cash Items | (33K) | 0 | 318K | 195K | 41K |
| Operating Cash Flow | (3.63M) | (18.53M) | (16.02M) | (28.47M) | (24.59M) |
| Capital Expenditures | (27K) | (171K) | (147K) | (4K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 9K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (27K) | (171K) | (147K) | (4K) | 9K |
| Debt Repayment | (268K) | (1.4M) | (811K) | (739K) | (353K) |
| Common Stock Issued | 44.22M | 5.32M | 5.33M | 24.35M | 37.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.25M | 1.62M | 0 | (46K) | (164K) |
| Financing Cash Flow | 53.2M | 5.55M | 4.52M | 23.57M | 36.57M |
| Effect of Forex Changes | (11K) | (1K) | 4K | 0 | 0 |
| Net Change in Cash | 49.53M | (13.16M) | (11.64M) | (4.91M) | 11.99M |
| Free Cash Flow | (3.66M) | (18.7M) | (16.17M) | (28.48M) | (24.59M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$23.5M
+ D&A$228.0K
+ Stock-Based Comp$2.1M
+ Deferred Tax$0
- Working Capital-$3.5M
+ Other Non-Cash$41.0K
= Operating Cash Flow-$24.6M
- Capex$0
= Free Cash Flow-$24.6M
Analysis
FY2025 free cash flow is -$24.6M. FCF conversion is 104.7% of net income. Operating cash flow was -$24.6M, with capex of $0. The largest bridge item is Working Capital at -$3.5M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Oct 22, 2026 | |
| 10-Q | Quarterly report | Aug 7, 2026 | |
| 8-K | Current report | Aug 6, 2026 |
Does CGTX generate free cash flow?
Cognition Therapeutics, Inc. (CGTX) generated -$24.59M of free cash flow in fiscal 2025.
How much operating cash flow does CGTX produce?
Operating cash flow was -$24.59M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.